Breath sniffing device may predict cancer drug success

NCT ID NCT04146064

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to develop a non-invasive, inexpensive way to select the right treatment for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
breathprint analysis using an electronic nose device
What this could lead to
If successful, this breath test could help doctors quickly and cheaply identify which patients are likely to benefit from immunotherapy, avoiding ineffective treatments.
What could go wrong
This is an early-stage, observational study. The breath test may not prove accurate enough for routine use, and results may not apply to all cancer types or treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.